ACAD Acadia Pharmaceuticals
$17.11 -2.73%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Point at or drag across the chart to read a day. EOD data.
1D
-2.73%
YTD
-35.90%
P/E
8.39
P/B
3.68
ROE
28%
Div yield
—
Beta
0.35
Market cap
$3.0B
RSI (14)
34
Next earnings
Feb 23, 2027
Same sector · Health Care
Compare ACAD with NVO and JNJ →Follow ACAD in the AlfaCat app
Watchlist, price and earnings alerts, the chart offline. Free, no account, no ads.
The economy behind it · United States
Economy this week on BullDozer →GDP, % on year
2.1
Q3 2026
Inflation, %
3.7
Sep 2026
Unemployment, %
3.9
Oct 2026
10-yr yield, %
5.13
Oct 2026
From BullDozer, our sister site for country statistics (open sources: OECD, IMF, Eurostat, ILO). Full United States profile →
Previous session
close of Nov 20, 2026 · EOD, no live order bookOpen
$17.47
Close
$17.11
Day high
$17.79
Day low
$17.05
Volume
1.9M
Latest headlines
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
Yahoo Finance · Nov 18
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Yahoo Finance · Nov 17
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
Yahoo Finance · Nov 16
Acadia Pharmaceuticals Fell While Sales Rose
Yahoo Finance · Nov 10
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Yahoo Finance · Nov 10
Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
Yahoo Finance · Nov 10
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Nov 5, 2026 View → 8-K Nov 4, 2026 View → 8-K Oct 23, 2026 View → 8-K Sep 24, 2026 View → 8-K Sep 11, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell ACAD. Try it in the Lab to size a position and see the risk.